Want to see PFE full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.68Last Year’s EPS
0.78Same Quarter Last Year
Based on 22 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational execution: a revenue and EPS beat, healthy underlying growth ex-COVID (~7%), substantial momentum from launched and acquired products (22% operational growth, $3.1B in Q1), multiple positive clinical readouts and meaningful strategic wins (Vyndamax settlement, favorable Belgian court ruling). Management balanced near-term challenges — LOE dynamics, COVID seasonality, higher accrued royalties and increased R&D spend — with clear actions to drive long-term growth (pipeline advancement, vaccine programs, manufacturing and cost-savings targets, BD capacity). Overall, positives around commercial performance, pipeline progress and legal/cash-flow clarity meaningfully outweigh the manageable near-term headwinds.Company Guidance
Revenue and EPS Beat in Q1 2026
Total revenues of $14.5 billion in Q1 2026, exceeding expectations and representing a 2% operational increase year-over-year. Reported diluted EPS was $0.47 and adjusted diluted EPS was $0.75, both above expectations.
Underlying Business Momentum Ex-COVID
Excluding COVID products, the underlying business delivered approximately 7% operational revenue growth in the quarter, signaling broad demand across key brands.
Strong Performance from Launched and Acquired Products
Launches and acquisitions generated $3.1 billion in Q1 revenue and grew ~22% operationally. Notable contributors: Nurtec grew 41% operationally and Seagen products grew 20% year-over-year operationally.
Clinical and R&D Progress — Multiple Positive Readouts
R&D delivered 3 positive Phase III readouts in early 2026 and encouraging mid-stage results. Key clinical wins: Padcev (EV-304) plus pembrolizumab reduced risk of recurrence or death by nearly 50% in cisplatin-eligible muscle-invasive bladder cancer; MagnetisMM-5 for Elrexfio showed significant improvement in progression-free survival in relapsed/refractory multiple myeloma; positive Phase II data for atirmociclib and tilrekimig. Management targets ~20 pivotal study starts, ~8 key data readouts and ~4 regulatory decisions in 2026.
Vyndamax Settlement and Belgian Court Ruling Improve Long-Term Profile
Settlement agreements related to Vyndamax patent matters and a favorable Belgian court ruling on Comirnaty contracts increase visibility into post-2028 cash flows and EPS. Management now expects to enter a 5-year period of high single-digit revenue CAGR starting in 2029 and reduced LOE impact (company noted LOE exposure is now closer to $14–15B vs prior ~$17B).
Vaccines and Pipeline Advancement
Initiated Phase III for a 25-valent pediatric pneumococcal conjugate candidate and advanced directly to a fifth-generation adult vaccine candidate covering 35 serotypes, with clinical development expected to begin this year — moves intended to sustain long-term leadership in vaccines.
Cost Savings, Margins and Capital Allocation Discipline
Adjusted gross margin ~76% in Q1 (mid-70s range guidance maintained). Manufacturing optimization Phase I expected to deliver ~$700 million in savings in 2026 with ~$175 million realized in Q1. Company reaffirmed plan to deliver ~$7.2 billion in total net cost savings by end of 2026. Capital actions: invested $2.5 billion in internal R&D in Q1, returned $2.4 billion to shareholders via dividend, sold ViiV stake for approx. $1.65 billion net proceeds (Q2) and reported BD capacity of about $7 billion; leverage ~2.8x and operating cash flow $2.6 billion in Q1.
Guidance Reaffirmed
Management reaffirmed full-year 2026 guidance: total revenues $59.5B–$62.5B and adjusted diluted EPS $2.80–$3.00 per share, reflecting confidence in execution while accounting for COVID seasonality.
PFE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PFE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $25.87 | $26.02 | +0.57% |
Feb 03, 2026 | $26.23 | $25.35 | -3.34% |
Nov 04, 2025 | $23.45 | $23.10 | -1.46% |
Aug 06, 2025 | $23.53 | $22.75 | -3.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pfizer Inc (PFE) report earnings?
Pfizer Inc (PFE) is schdueled to report earning on Aug 04, 2026, Before Open (Confirmed).
What is Pfizer Inc (PFE) earnings time?
Pfizer Inc (PFE) earnings time is at Aug 04, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PFE EPS forecast?
PFE EPS forecast for the fiscal quarter 2026 (Q2) is 0.68.
